{"log_id": 8113209382169604861, "direction": 0, "words_result_num": 47, "words_result": [{"probability": {"variance": 0.006159, "average": 0.960989, "min": 0.623968}, "location": {"width": 884, "top": 195, "height": 34, "left": 162}, "words": "和4级为5%如果有不能解释的呼吸症状:如干咳、呼吸困难、湿吵音,或放射性肺浸润,应中止奥沙利铂给药直至进"}, {"probability": {"variance": 0.014064, "average": 0.933875, "min": 0.512167}, "location": {"width": 316, "top": 233, "height": 22, "left": 171}, "words": "一步的肺部检查排除间质性肺病玻肺纤维化"}, {"probability": {"variance": 0.072493, "average": 0.772395, "min": 0.392355}, "location": {"width": 52, "top": 265, "height": 21, "left": 162}, "words": "肝性"}, {"probability": {"variance": 0.027865, "average": 0.9261, "min": 0.40803}, "location": {"width": 840, "top": 283, "height": 34, "left": 194}, "words": "毒性(定义为肝酶升)可能与奥沙利铂联合治疗有关。在辅助治疗试验宁证实有肝毒性,观察到转氨酶(57%"}, {"probability": {"variance": 0.011844, "average": 0.946312, "min": 0.512751}, "location": {"width": 836, "top": 312, "height": 33, "left": 210}, "words": "和碱性磷酸酶(42%:20%)的增加在奥沙利铂联合治疗组比对照治疗组中更常见。两个治疗组胆红素增加的发生"}, {"probability": {"variance": 0.013575, "average": 0.941422, "min": 0.490215}, "location": {"width": 881, "top": 340, "height": 36, "left": 165}, "words": "半相似。肝脏活组织检查的变化包括:紫癜,结节性再生性增生或窦状隙变化,实周纤维化和静脉闭塞性损伤。如果肝"}, {"probability": {"variance": 0.001519, "average": 0.977028, "min": 0.819437}, "location": {"width": 748, "top": 372, "height": 31, "left": 165}, "words": "功能检查结果异常或有门静脉高压,其不能用肝转移解释。应考虑肝血管疾病,如可能,应进行观察"}, {"probability": {"variance": 0.001208, "average": 0.980306, "min": 0.881448}, "location": {"width": 176, "top": 408, "height": 23, "left": 165}, "words": "上市后经验(发生率未知"}, {"probability": {"variance": 0.01075, "average": 0.955731, "min": 0.663346}, "location": {"width": 150, "top": 438, "height": 22, "left": 165}, "words": "血液和淋巴系统疾病"}, {"probability": {"variance": 0.021815, "average": 0.886451, "min": 0.536122}, "location": {"width": 137, "top": 465, "height": 21, "left": 197}, "words": "溶血尿器素综合征"}, {"probability": {"variance": 0.04956, "average": 0.702742, "min": 0.400031}, "location": {"width": 96, "top": 494, "height": 24, "left": 167}, "words": "系统疾"}, {"probability": {"variance": 0.053588, "average": 0.766048, "min": 0.534557}, "location": {"width": 38, "top": 523, "height": 21, "left": 198}, "words": "惊厥"}, {"probability": {"variance": 0.033688, "average": 0.878922, "min": 0.439778}, "location": {"width": 205, "top": 551, "height": 22, "left": 166}, "words": "血小板、出血以及血"}, {"probability": {"variance": 0.012422, "average": 0.955799, "min": 0.464274}, "location": {"width": 395, "top": 577, "height": 27, "left": 200}, "words": "在接受抗凝剂治疗的患者中INR和凝血酶原时间延长"}, {"probability": {"variance": 0, "average": 0.936421, "min": 0.936421}, "location": {"width": 84, "top": 610, "height": 24, "left": 180}, "words": "忌"}, {"probability": {"variance": 0.006246, "average": 0.959229, "min": 0.76596}, "location": {"width": 186, "top": 637, "height": 24, "left": 167}, "words": "奥沙利铂禁用于以下患者"}, {"probability": {"variance": 0.004195, "average": 0.969079, "min": 0.754609}, "location": {"width": 388, "top": 664, "height": 28, "left": 153}, "words": "已知对奥沙利铂过敏或对其它铂类化合物过敏者"}, {"probability": {"variance": 0.076575, "average": 0.759267, "min": 0.372127}, "location": {"width": 184, "top": 688, "height": 42, "left": 139}, "words": "乳期妇女"}, {"probability": {"variance": 0.001665, "average": 0.958225, "min": 0.896205}, "location": {"width": 175, "top": 716, "height": 32, "left": 175}, "words": "【注意事项"}, {"probability": {"variance": 0.015431, "average": 0.939906, "min": 0.597302}, "location": {"width": 222, "top": 754, "height": 23, "left": 167}, "words": "特殊警告和特殊使用注意事项"}, {"probability": {"variance": 0.005849, "average": 0.973917, "min": 0.571928}, "location": {"width": 566, "top": 793, "height": 31, "left": 194}, "words": "奥沙利铂应在专门的肿瘤机构内应用,井在有经验的肿瘤医生的监督下使用"}, {"probability": {"variance": 0.001022, "average": 0.979237, "min": 0.893303}, "location": {"width": 354, "top": 839, "height": 27, "left": 167}, "words": "用于孕妇时,请参见【孕妇及哺乳期妇女用药】"}, {"probability": {"variance": 0.007638, "average": 0.96859, "min": 0.462536}, "location": {"width": 833, "top": 862, "height": 33, "left": 201}, "words": "对重度肾功能不全患者应用尚乏足够的安全性研究的资料。因此、此类忠者用药前应该权衡利弊。此种情况下"}, {"probability": {"variance": 0.019628, "average": 0.917927, "min": 0.438874}, "location": {"width": 715, "top": 895, "height": 27, "left": 201}, "words": "必须密切监测肾功能,并且奥沙利铂推荐起始剂量为65mg/m3(见【用法用量】中“危人群”)"}, {"probability": {"variance": 0.002067, "average": 0.976207, "min": 0.821894}, "location": {"width": 851, "top": 920, "height": 36, "left": 201}, "words": "治疗过程中应严密监测过敏症状。过敏症状可在任何周期发生。一旦发生任何过敏反应,应立即停止给药,并给予"}, {"probability": {"variance": 0.012171, "average": 0.955164, "min": 0.537625}, "location": {"width": 394, "top": 956, "height": 29, "left": 202}, "words": "积极的对症治疗,井禁止在这些患者中再用奥沙利铂"}, {"probability": {"variance": 0.004367, "average": 0.976343, "min": 0.644632}, "location": {"width": 479, "top": 985, "height": 30, "left": 202}, "words": "如有外渗发生,应立即终止滴注并采取局部处理措施以改善症状"}, {"probability": {"variance": 0.010808, "average": 0.956025, "min": 0.388368}, "location": {"width": 850, "top": 1010, "height": 35, "left": 203}, "words": "应仔细监测奥沙利铂的感觉性外周神经性,特别是与其它有特定神经系统毒性的药物合用时。每次治疗前都要进"}, {"probability": {"variance": 0.00202, "average": 0.973771, "min": 0.840897}, "location": {"width": 239, "top": 1049, "height": 23, "left": 204}, "words": "行神经系统检查,以后定期复查"}, {"probability": {"variance": 0.001825, "average": 0.982446, "min": 0.730691}, "location": {"width": 829, "top": 1068, "height": 36, "left": 205}, "words": "如果以2小时内滴注完奥沙利铂的速度给药时,患者出现急性喉痉挛,下次滴注时,应将滴注时间延长至6小时"}, {"probability": {"variance": 0.011967, "average": 0.958613, "min": 0.409699}, "location": {"width": 846, "top": 1098, "height": 35, "left": 206}, "words": "为了防止出现这样的痉挛,应该告知患者,在奥沙利给药期间或给药后数小时内,避免暴于冷环境中,避免进"}, {"probability": {"variance": 0.016, "average": 0.950763, "min": 0.500471}, "location": {"width": 233, "top": 1136, "height": 26, "left": 208}, "words": "食未加工的冷的食物或/和冷饮"}, {"probability": {"variance": 0.008636, "average": 0.955258, "min": 0.573116}, "location": {"width": 854, "top": 1155, "height": 38, "left": 201}, "words": "如果患者出现神经系统症状(感觉障碍、痉挛),那么依据症状持续的时间和严重程度推荐以下方法调整奥沙利铂的剂"}, {"probability": {"variance": 0, "average": 0.992309, "min": 0.992309}, "location": {"width": 21, "top": 1199, "height": 19, "left": 197}, "words": "量"}, {"probability": {"variance": 0.01387, "average": 0.950145, "min": 0.43638}, "location": {"width": 822, "top": 1215, "height": 37, "left": 235}, "words": "如果症状持续7天以上而且牧严重,应将奥沙利铂的剂量从85mg/m2减至65mg/m2(晚期瘤化疗)或至"}, {"probability": {"variance": 0.014915, "average": 0.933684, "min": 0.57514}, "location": {"width": 150, "top": 1257, "height": 22, "left": 239}, "words": "75mg/m2(轴助化疗)"}, {"probability": {"variance": 0.003926, "average": 0.961963, "min": 0.742873}, "location": {"width": 819, "top": 1276, "height": 35, "left": 236}, "words": "如果无功能损害的感觉异常一直持续到下一周期,奥沙利铂的剂从85mg/m2减至65mg/m2晚期肿瘤化疗)或"}, {"probability": {"variance": 0.008653, "average": 0.943976, "min": 0.65144}, "location": {"width": 172, "top": 1317, "height": 22, "left": 238}, "words": "至75mg/m2(助化疗)"}, {"probability": {"variance": 0.015011, "average": 0.950234, "min": 0.483684}, "location": {"width": 546, "top": 1339, "height": 31, "left": 237}, "words": "如果出现功能不全的感觉异常一直持续到下一周期,应停止应用奥沙利伯"}, {"probability": {"variance": 0.00453, "average": 0.971523, "min": 0.730138}, "location": {"width": 564, "top": 1369, "height": 31, "left": 237}, "words": "如果在停止使用奥沙利铂后,这些症状有所改善,可考虑继续奥沙利铂治疗"}, {"probability": {"variance": 0.009034, "average": 0.953828, "min": 0.587871}, "location": {"width": 848, "top": 1395, "height": 36, "left": 208}, "words": "应告知患者治疗停止后,周目觉神经病变症状可能持续存在。辅助治疗停止后,局部、中度感觉异常或影响日常"}, {"probability": {"variance": 0.00179, "average": 0.97873, "min": 0.839396}, "location": {"width": 257, "top": 1435, "height": 22, "left": 209}, "words": "活动的感觉异常可能持续3年以上"}, {"probability": {"variance": 0.009409, "average": 0.960797, "min": 0.510621}, "location": {"width": 846, "top": 1455, "height": 34, "left": 210}, "words": "可逆性后部白质脑病综合征(RPLS,也称为大脑后部可逆性脑病综合征,即PRES)的征兆和症状可能是头痛、智力改"}, {"probability": {"variance": 0.007812, "average": 0.940713, "min": 0.690131}, "location": {"width": 599, "top": 1488, "height": 33, "left": 209}, "words": "变、掘痫、视力异常(模糊至失明)、伴或不伴高血压。RPLS可通过脑部造确诊"}, {"probability": {"variance": 0.007627, "average": 0.961924, "min": 0.679958}, "location": {"width": 570, "top": 1517, "height": 34, "left": 209}, "words": "胃肠道毒性,主要表现为恶心和呕吐,建议给予预防性和或治疗性止吐用药"}, {"probability": {"variance": 0.015362, "average": 0.946497, "min": 0.504752}, "location": {"width": 850, "top": 1545, "height": 35, "left": 209}, "words": "严重的腹泻和或呕吐可能会引起脱水、麻丹性肠梗阻、肠闭塞、低血钾、代谢性酸中毒以及肾功能异常,特别当奥"}, {"probability": {"variance": 0.01053, "average": 0.952405, "min": 0.569091}, "location": {"width": 462, "top": 1580, "height": 29, "left": 210}, "words": "沙利铂与5-氟尿嘧啶联合应用时,发生这些情况的可能性更大"}], "language": 3}